ALNY — Alnylam Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $18.19bn
- $16.77bn
- $1.83bn
- 71
- 12
- 35
- 34
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -886 | -858 | -853 | -1,131 | -440 |
Depreciation | |||||
Non-Cash Items | 188 | 221 | 326 | 581 | 480 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 402 | -12.7 | -163 | -35.6 | 10.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -278 | -615 | -642 | -541 | 104 |
Capital Expenditures | -140 | -70.4 | -76.4 | -72.1 | -62.2 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -278 | -365 | -197 | 241 | -274 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -418 | -436 | -273 | 169 | -336 |
Financing Cash Flow Items | — | 495 | 501 | 31 | 24.7 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 823 | 995 | 1,247 | 426 | 172 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 127 | -50.6 | 323 | 46.4 | -53.7 |